ArticleOncotarget2015

Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.

Hao Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.